ArriVent BioPharma, Inc. (AVBP)
Healthcare
Biotechnology
29.80 $
-2.7%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns ArriVent BioPharma, Inc. (AVBP)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 63.9% of the shares are freely tradable; institutional investors hold 95.9%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
95.9%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
1.6%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
63.9%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
17.9%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
47Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Suvretta Capital Management, LLC | 9.45 | 4,401,083 | +7.2 | 03/31/2026 |
| Hillhouse Capital Advisors, Ltd. | 8.44 | 3,929,117 | -12.4 | 12/31/2025 |
| Orbimed Advisors, LLC | 6.50 | 3,027,328 | +0.0 | 03/31/2026 |
| FMR Inc | 6.48 | 3,016,132 | -18.6 | 03/31/2026 |
| BlackRock Inc | 5.43 | 2,530,301 | +6.6 | 03/31/2026 |
| Octagon Capital Advisors LP | 4.23 | 1,971,054 | +0.0 | 03/31/2026 |
| Novo A/S | 4.17 | 1,942,142 | +0.0 | 03/31/2026 |
| Vanguard Group Inc | 4.01 | 1,869,266 | -7.9 | 12/31/2025 |
| Sofinnova Ventures | 3.64 | 1,696,752 | +0.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| HBM Healthcare Investments AG Ord | 5.47 | 2,548,185 | +15.7 | 03/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.